Author/Authors :
Ba̧dziul, Dorota Medical Faculty - University of Rzeszow - Rejtana - Rzeszow, Poland , Jakubczyk, Paweł Faculty of Mathematics and Natural Sciences - University of Rzeszow - Rejtana - Rzeszow, Poland , Chotorlishvili, Levan Martin-Luther University Halle-Wittenberg - Halle, Germany , Toklikishvilie, Zaza Department of Physics - Tbilisi State University - Chavchavadze - Tbilisi, Georgia , Traciak, Julian Faculty of Mathematics and Applied Physics - Rzeszow University of Technology - Al. Powstancow Warszawy - Rzeszow, Poland , Jakubowicz-Gil, Joanna Maria Curie-Skłodowska University - Plac Marii Curie-Skłodowskiej - Lublin, Poland , Chmiel-Szajner, Sylwia Medical Faculty - University of Rzeszow - Rejtana - Rzeszow, Poland
Abstract :
Basic immunology research over several decades has led to an improved understanding of tumour recognition by components of
the immune system and mechanism of tumour evasion from immune detection. These findings have ultimately led to creating
antitumour immunotherapies in patients with different kind of cancer including prostate cancer. The increasing number of
reports confirms that immune-based therapies have clinical benefit in patients with prostate cancer with potentially less toxicity in
comparison with traditional systemic treatments including surgical resection, chemotherapy, or radiotherapy in various forms.
(is review focuses on the possibility of modulation of the optimal immunotherapy based on vaccination strategy adopted to
individual patients in order to increase quality and quantity of their life.
Keywords :
Prostate , Vaccination , Immunotherapy , PSA
